A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Imiglitazar; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Takeda Global Research and Development Center
- 18 Dec 2008 Planned patient number added (348) as reported by ClinicalTrials.gov.
- 18 Dec 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
- 16 Oct 2008 New trial record.